Have we improved in preventing and treating acute graft-versus-host disease?

Current Opinion in Hematology

Volumn 18, Issue 6, 2011, Pages 408-413

  Perez, Lia ^a,b   Anasetti, Claudio ^a,b   Pidala, Joseph ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

graft versus host disease; hematopoietic cell transplantation; regulatory T cells

Indexed keywords

BECLOMETASONE DIPROPIONATE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; DENILEUKIN DIFTITOX; ETANERCEPT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; DRUG DOSE REDUCTION; EFFECTOR CELL; HUMAN; PHOTOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW;

ACUTE DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; T-LYMPHOCYTES, REGULATORY;

EID: 80054746763     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32834b6196     Document Type: Review

References (39)

1. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96:2062-2068.
2. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92:2303-2314. (Pubitemid 28452971)
3. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 2011; 117:1061-1070. The authors have demonstrated the feasibility of donor Treg expansion and safety of infusion of such cells in the setting of umbilical cord blood transplantation.
4. Rodriguez R, Nakamura R, Palmer JM, et al. A phase II pilot study of tacrolimus/ sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010; 115:1098-1105.
5. Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008; 112:1515-1521.
6. Shaughnessy PJ, Bolwell BJ, van Besien K, et al. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45:1068-1076.
7. Jakubowski AA, Small TN, Kernan NA, et al. T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant 2011; 17:1335-1342. The authors demonstrate marked protection from GVHD with aggressive T-cell depletion in unrelated donor transplantation.
8. Devine SM, Carter S, Soiffer RJ, et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303. Biol Blood Marrow Transplant 2011; 17:1343-1351. The authors report mature results from CTN 0303 in which there is a notably low risk of chronic GVHD with T-cell depletion as sole GVHD prophylaxis.
9. Litzow MR, Perez WS, Klein JP, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 2002; 119:1115-1124. (Pubitemid 35463841)
10. Parmar S, Andersson BS, Couriel D, et al. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: A phase I/II controlled, adaptively randomized study. J Clin Oncol 2011; 29:294-302. The authors employ a novel endpoint (composite of patients being alive, engrafted, in remission, without GVHD at 100 days after HCT, and with no grade 3 GVHD at any time) in this trial. Risk for GVHD in pentostatin-treated cohorts is not significantly different compared to control.
11. Perkins J, Field T, Kim J, et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graftversus- host disease prophylaxis. Biol Blood Marrow Transplant 2010; 16:937-947. The authors demonstrate that MMF spares toxicity associated with MTX, but no significant differences in acute or chronic GVHD are observed.
12. Luznik L, Bolanos-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010; 115:3224-3230. The authors demonstrate that single agent prophylaxis with high-dose posttransplantation cyclophosphamide effectively prevents acute and chronic GVHD.
13. Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109:4119-4126. (Pubitemid 46743372)
14. Hings IM, Severson R, Filipovich AH, et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 1994; 58:437-442. (Pubitemid 24271531)
15. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biol Blood Marrow Transplant 2002; 8:387-394.
16. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990; 76:1464-1472. (Pubitemid 20364008)
17. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome. Blood 1990; 75:1024-1030. (Pubitemid 20067206)
18. Saliba RM, Couriel DR, Giralt S, et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant 2011 [Epub ahead of print]. The authors demonstrate the prognostic significance of response to therapy in determining acute GVHD outcomes.
19. Pidala J, Anasetti C. Glucocorticoid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16:1504-1518.
20. Busca A. The use of monoclonal antibodies for the treatment of graft-versushost disease following allogeneic stem cell transplantation. Expert Opin Biol Ther 2011; 11:687-697.
21. Horwitz EM, Maziarz RT, Kebriaei P. MSCs in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17:S21-29.
22. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graftversus- host disease with high- or low-dose 6-methylprednisolone: A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92:2288-2293. (Pubitemid 28452969)
23. Hings IM, Filipovich AH, Miller WJ, et al. Prednisone therapy for acute graftversus- host disease: Short- versus long-term treatment. A prospective randomized trial. Transplantation 1993; 56:577-580. (Pubitemid 23293018)
24. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: Significant survival advantage for day +5 responders and no advantage for nonresponders receiving antithymocyte globulin. Blood 2006; 107:4177-4181. (Pubitemid 43726830)
25. Cahn JY, Labopin M, Mandelli F, et al. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: A retrospective analysis of the European Bone Marrow Transplant Group. Blood 1995; 85:575-579.
26. Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996; 88:824-830. (Pubitemid 26333302)
27. Cragg L, Blazar BR, Defor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6:441-447.
28. Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: Results of a randomized trial. Blood 2004; 104:1559-1564. (Pubitemid 39166538)
29. Uberti JP, Ayash L, Ratanatharathorn V, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graftversus- host disease. Biol Blood Marrow Transplant 2005; 11:680-687. (Pubitemid 41194976)
30. Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111:2470-2475. (Pubitemid 351451462)
31. Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: A randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009; 114:511-517.
32. Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial. Blood 1997; 89:3880-3887. (Pubitemid 27227115)
33. Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versushost disease with low-dose prednisone does not compromise patient outcomes. Blood 2009; 113:2888-2894.
34. McDonald GB, Bouvier M, Hockenbery DM, et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: A randomized, controlled trial. Gastroenterology 1998; 115:28-35. (Pubitemid 28307284)
35. Hockenbery DM, Cruickshank S, Rodell TC, et al. A randomized, placebocontrolled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007; 109:4557-4563. (Pubitemid 46743427)
36. Wang Y, Xu LP, Liu KY, et al. Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: Safety and feasibility. Bone Marrow Transplant 2010; 46:892-898.
37. Pidala J, Kim J, Anasetti C. Sirolimus as primary treatment of acute graftversus- host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15:881-885.
38. Cutler C, Antin JH. Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: An update. Curr Opin Hematol 2010; 17:500-504.
39. Pidala J, Tomblyn M, Nishihori T, et al. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica 2011 [Epub ahead of print]. The authors report that SIR has activity as a sole immune suppressive agent in the primary therapy of acute GVHD.